Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 18/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631993 | 0.86 | OPRK1 (1.00) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL17870633 | 0.86 | OPRK1 (1.00) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL8089140 | 0.84 | OPRK1 (0.73) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL5631916 | 0.84 | OPRK1 (0.80) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL6478584 | 0.79 | OPRK1 (0.82) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL5631924 | 0.79 | OPRK1 (0.82) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5842166 | 0.79 | OPRK1 (0.98) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5842170 | 0.79 | OPRK1 (0.98) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL5843674 | 0.79 | OPRK1 (1.00) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 | |
| SCHEMBL5843678 | 0.79 | OPRK1 (1.00) | OPRK1CYP2D6OPRM1OPRD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 886/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.